^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PRDM1 mutation

    i
    Other names: PRDM1, PR/SET Domain 1, PRDI-BF1, PR Domain Containing 1, With ZNF Domain, PR Domain Zinc Finger Protein 1, PR Domain 1, BLIMP1, Beta-Interferon Gene Positive-Regulatory Domain I Binding Factor, Beta-Interferon Gene Positive Regulatory Domain I-Binding Factor, Positive Regulatory Domain I-Binding Factor 1, B-Lymphocyte-Induced Maturation Protein 1, PR Domain-Containing Protein 1, PRDI-Binding Factor-1
    Entrez ID:
    639
    over2years
    Spectrum and Clinical Features of Gene Mutations in Chinese Follicular Lymphoma (ASH 2023)
    For patients who received R-CHOP-like regimens, the multivariate COX proportional hazard modeling identified TP53, TNFAIP3, and SOCS1 mutations as independent risk factors of PFS (HR 6.76, 95% CI 1.81 to 25.18, p =0.004; HR 3.68, 95% CI 1.06 to 12.82, p =0.041; HR 5.07, 95% CI 1.81 to 21.73, p =0.029). Our study depicted genomic characterization of real-world Chinses FL patients and demonstrated TP53, TNFAIP3 and SOCS1 mutations can help identify high-risk patients.
    Clinical • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CARD11 (Caspase Recruitment Domain Family Member 11) • NOTCH3 (Notch Receptor 3) • TNFAIP3 (TNF Alpha Induced Protein 3) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1)
    |
    NOTCH3 mutation • PRDM1 mutation • SOCS1 mutation
    |
    Rituxan (rituximab)
    over2years
    Clinicopathologic and mutational profiles of primary breast diffuse large B cell lymphoma in a male patient: case report and literature review. (PubMed, World J Surg Oncol)
    We reported a relatively rare PB-DLBCL in a male, non-GBC phenotype, dual-expression type. It is worth mentioning that this case had IgH/BCL6 fusion, nonsense mutations in TNFAIP3, frameshift mutations in PRDM1, and missense mutations in CREBBP, DTX1, and FOXO1. To the best of our knowledge, this case is the first report of genomic mutational profiles of PB-DLBCL in males.
    Review • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • CREBBP (CREB binding protein) • TNFAIP3 (TNF Alpha Induced Protein 3) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • PRDM1 (PR/SET Domain 1)
    |
    CD20 positive • BCL2 positive • CREBBP mutation • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • PRDM1 mutation • BCL6 positive • BCL6 fusion
    |
    Rituxan (rituximab) • cytarabine • Inokai (orelabrutinib)
    almost3years
    Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma. (PubMed, Signal Transduct Target Ther)
    Genetic subtype-guided targeted agents achieved encouraging clinical response when combined with immunochemotherapy. Collectively, LymphPlex provided high efficacy and feasibility, representing a step forward to the mechanism-based targeted therapy in DLBCL.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • KMT2D (Lysine Methyltransferase 2D) • CD79B (CD79b Molecule) • B2M (Beta-2-microglobulin) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD70 (CD70 Molecule) • EP300 (E1A binding protein p300) • TNFAIP3 (TNF Alpha Induced Protein 3) • GNA13 (G Protein Subunit Alpha 13) • IRF8 (Interferon Regulatory Factor 8) • PIM1 (Pim-1 Proto-Oncogene) • TNFRSF14 (TNF Receptor Superfamily Member 14) • CCND3 (Cyclin D3) • IRF4 (Interferon regulatory factor 4) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1) • STAT6 (Signal transducer and activator of transcription 6) • TNFRSF18 (TNF Receptor Superfamily Member 18) • BTG2 (BTG Anti-Proliferation Factor 2) • DDX3X (DEAD-Box Helicase 3 X-Linked) • TBL1XR1 (TBL1X Receptor 1) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    TP53 mutation • ARID1A mutation • NOTCH1 mutation • EZH2 mutation • MYC expression • MYC rearrangement • STAT3 mutation • GNA13 mutation • PRDM1 mutation • IRF8 mutation • BCL2 fusion • BCL6 fusion
    almost4years
    GENOTYPING ON CIRCULATING TUMOR DNA IMPROVES MUTATION DETECTION RATE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (EHA 2022)
    In fact, 35.3% (6/17) MCD DLBCLs were only identified by ctDNA but not by gDNA, suggesting the addition of ctDNA genotyping substantially improved the detection rate of MCD subtype (figure 1). Conclusion Our study highlights the clinical application of ctDNA, in particular in patients with high-risk and early relapsed or refractory diseases, where ctDNA analysis represents a complementary approach to tissue biopsy gDNA genotyping.
    Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • B2M (Beta-2-microglobulin) • EP300 (E1A binding protein p300) • PRDM1 (PR/SET Domain 1)
    |
    TP53 mutation • EP300 mutation • PRDM1 mutation
    4years
    A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. (PubMed, Blood Adv)
    In conclusion, we have identified a new pediatric type of PCNS-LBCL that is molecularly distinct from PCNS-LBCL occurring in adults, based on an absence of MYD88 mutation, CDKN2A/B homozygous deletion, deletion of HLA gene cluster, and paucity of CD79B and PRDM1 mutations, along with an enrichment for TP53, NFKBIE, and GNA13 mutations. Patients with pediatric type, MYD88-wildtype PCNS-LBCL often have long-term survival compared to their adult counterparts.
    Clinical • Clinical data • Journal
    |
    TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • GNA13 (G Protein Subunit Alpha 13) • PRDM1 (PR/SET Domain 1) • NFKBIE (NFKB Inhibitor Epsilon)
    |
    TP53 mutation • CDKN2A deletion • MYD88 mutation • CDKN2A mutation • CD79B mutation • GNA13 mutation • PRDM1 mutation • MYD88 wild-type
    almost5years
    [VIRTUAL] Integrative genomic analysis of diffuse large B cell lymphoma (DLBCL) identifies recurrent oncogenic alterations associated with distinct immune-related clusters (AACR 2021)
    A20 lymphomas with inducible c-Myc activation (A20MycER) contained fewer CD8+ T cells following tamoxifen versus control treatment, confirming our computational findings... Through computational analyses in a large genomic dataset, we have defined unique immune-related DLBCL clusters and associated recurrent genomic alterations. Through ongoing studies in murine models, we aim to elucidate mechanisms by which particular oncogenic alterations in lymphoma cells shape the DLBCL immune landscape and impact CBT response
    PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • FOXO1 (Forkhead box O1) • SOCS1 (Suppressor Of Cytokine Signaling 1) • PRDM1 (PR/SET Domain 1) • KLHL6 (Kelch Like Family Member 6)
    |
    PD-L1 expression • TP53 mutation • PD-L1 amplification • PRDM1 mutation
    |
    tamoxifen